Novartis Ag

Arvind Kinhikar

Stefan De Buck

Martin Kaul

Alessandra Vitaliti Garami

Maciej Cabanski

Souvik Bhattacharya

Bruno Bieth

Bruno Cenni

Andrijana Radivojevic

Julian Storim

Thomas Severin

The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

The present disclosure relates to methods for treating Sjögren's Syndrome disease using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Sjögren's Syndrome patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor

Growing community of inventors

Cambridge, MA, United States of America

Arvind Kinhikar